Kerri Fitzgerald

DocwireNews

A study presented at the 2020 Society of Hematologic Oncology Annual Meeting found that the addition of ixazomib to lenalidomide and dexamethasone significantly extended progression-free survival (PFS; primary endpoint) in transplant-ineligible patients with newly diagnosed multiple myeloma (MM) with high-risk cytogenetics.
The randomized, phase III TOURMALINE-MM2 trial included 705 adults with newly diagnosed MM who were not eligible for autologous hematopoietic cell transplantation. Patients were randomized to receive lenalidomide 25 mg and dexamethasone 40 mg either with (n=351; median age, 73 years) or without (placebo group; n=354; median age, 74 years) ixazomib 4 mg. After 18 cycles, dexamethasone was discontinued, and patients received reduced doses of ixazomib and lenalidomide until disease progression or unacceptable toxicity.
Median follow-up was 55.3 months in the ixazomib group and 55.8 months in the placebo group. Median PFS was longer among ixazomib-treated patients than placebo (35.3 months vs. 21.8 months; hazard ratio [HR], 0.83), although this was not statistically significant.
Overall response rates were similar in the ixazomib and placebo groups (82% vs. 80%). However, a higher percentage of ixazomib-treated patients achieved complete response (26% vs. 14%; odds ratio [OR], 2.1; P&lt;0.001) or very-good partial response or better (63% vs. 48%; OR, 1.87; P&lt;0.001). Median time to progression was 45.8 months in the ixazomib group versus 26.8 months in the placebo group (HR, 0.736; P=0.008).
Longer median time to progression was observed in the ixazomib group (45.8 months vs. 26.8 months; HR, 0.73; P=0.008). Median overall survival did not differ significantly between the groups (57.8 months vs. 58.6 months, respectively; HR, 0.99).
Among a cohort of patients with high-risk cytogenetics (38% in ixazomib group and 41% in placebo group), there was a statistically significant PFS benefit in the ixazomib cohort (median, 23.8 months vs. 18.0 months; HR, 0.69; P=0.019).
More patients in the ixazomib-treated group experienced grade ≥3 treatment-related adverse events (AEs; 88% vs. 81%) and treatment-related AEs that resulted in treatment discontinuation (35% vs. 27%). Eight percent of patients in the ixazomib group died during the study compared with 6% of those in the placebo cohort.
“[Ixazomib plus lenalidomide and dexamethasone] is a feasible treatment option for certain transplant-ineligible patients who could benefit from an all-oral triplet combination,” the authors concluded.

Cecilia Brown

Team Develops Model to Enhance Prediction of KRAS Mutations in Patients With NSCLC

KRAS+ NSCLC

Amit Goyal, MD

DCB-BIF Trial Results Favor Use of Drug-Coated Balloons to Rescue Jeopardized Side-branches After Provisional Bifurcation Stenting

Interventional Cardiology

Rob Dillard

Novel Method for Predicting Immunotherapy Response in Melanoma Patients

Melanoma

Latest News

Does the Addition of Ixazomib to Lenalidomide and Dexamethasone Improve Survival in MM?

Oncology

A study presented at the 2020 Society of Hematologic Oncology Annual Meeting found that the addition of ixazomib to lenalidomide and dexamethasone significantly extended ...

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe